Last quarter (Q4 2022), Argenica Therapeutics Ltd's total revenue was AU$―, a decrease of ― from previous quarter. In Q4, Argenica Therapeutics Ltd's net income was AU$―. See Argenica Therapeutics Ltd’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 22	Jun 21
Total Revenue	-	-	-
Cost of Revenue	-	-	-
Gross Profit	-	-	-
Operating Expense	-	AU$ 4.35M	AU$ 1.33M
Operating Income	-	AU$ -4.35M	AU$ -1.33M
Net Non Operating Interest Income Expense	-	AU$ 1.68K	AU$ 182.00
Other Income Expense	-	AU$ 259.10K	AU$ 296.07K
Pretax Income	-	AU$ -4.09M	AU$ -1.03M
Tax Provision	-	AU$ 0.00	AU$ 54.00
Earnings From Equity Interest Net Of Tax	-	-	-
Net Income Common Stockholders	-	AU$ -4.09M	AU$ -1.03M
Basic EPS	-	AU$ -0.06	AU$ -0.03
Diluted EPS	-	AU$ -0.06	AU$ -0.03
Basic Average Shares	-	AU$ 73.93M	AU$ 35.40M
Diluted Average Shares	-	AU$ 73.93M	AU$ 35.40M
Dividend Per Share	-	-	-
Total Operating Income As Reported	-	-	-
Reported Normalized Basic E P S	-	-	-
Reported Normalized Diluted E P S	-	-	-
Rent Expense Supplemental	-	-	-
Total Expenses	-	-	-
Net Income From Continuing And Discontinued Operation	-	AU$ -4.09M	AU$ -1.03M
Normalized Income	-	AU$ -4.09M	AU$ -1.03M
Interest Expense	-	AU$ 822.00	AU$ 20.00
EBIT	-	AU$ -4.09M	AU$ -1.03M
EBITDA	-	AU$ -4.09M	AU$ -1.03M

Currency in AUD

Argenica Therapeutics Ltd Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing